{"protocolSection": {"identificationModule": {"nctId": "NCT02808819", "orgStudyIdInfo": {"id": "D3250C00037"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "A Safety Extension Study With Benralizumab for Asthmatic Adults on Inhaled Corticosteroid Plus Long-acting \u03b22 Agonist", "officialTitle": "A Multicenter, Open-label, Safety Extension Study With Benralizumab (MEDI-563) for Asthmatic Adults on Inhaled Corticosteroid Plus Long-acting \u03b22 Agonist (MELTEMI)", "acronym": "MELTEMI"}, "statusModule": {"statusVerifiedDate": "2021-03", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2016-06-30", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2020-06-18", "type": "ACTUAL"}, "completionDateStruct": {"date": "2020-06-18", "type": "ACTUAL"}, "studyFirstSubmitDate": "2016-06-07", "studyFirstSubmitQcDate": "2016-06-17", "studyFirstPostDateStruct": {"date": "2016-06-22", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2021-02-12", "resultsFirstSubmitQcDate": "2021-03-18", "resultsFirstPostDateStruct": {"date": "2021-04-13", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2021-03-18", "lastUpdatePostDateStruct": {"date": "2021-04-13", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to continue to characterize the safety profile of benralizumab administration and monitor the pharmacodynamic activity of the drug in those asthma patients who remain on treatment for at least 16 weeks and not more than 40 weeks in the predecessor study D3250C00021 (BORA, NCT02258542).", "detailedDescription": "This is an open-label safety extension study designed to evaluate the safety and tolerability of a fixed 30 mg dose of benralizumab administered subcutaneously (SC) in severe asthma patients on inhaled corticosteroid and long-acting \u03b22 agonist (ICS-LABA) therapy with or without chronic oral corticosteroids (OCS) and/or other asthma controllers. All patients will receive active drug on the same dosing regimen they received in BORA (NCT02258542). In order to protect the blind of BORA, patients will remain blinded to treatment regimen allocation until they have completed all end of treatment (EOT) assessments in BORA and signed informed consent for participation in this study, after which treatment allocation will be unblinded to both the investigator and the patient."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Asthma", "Bronchial Diseases", "Respiratory Tract Diseases", "Lung Diseases", "Obstructive Lung Diseases"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "NON_RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "OTHER", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 447, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Benralizumab Arm A", "type": "OTHER", "description": "Benralizumab administered subcutaneously every 4 weeks", "interventionNames": ["Biological: Benralizumab"]}, {"label": "Benralizumab Arm B", "type": "OTHER", "description": "Benralizumab administered subcutaneously every 8 weeks", "interventionNames": ["Biological: Benralizumab"]}], "interventions": [{"type": "BIOLOGICAL", "name": "Benralizumab", "description": "Benralizumab administered subcutaneously every 4 weeks", "armGroupLabels": ["Benralizumab Arm A"]}, {"type": "BIOLOGICAL", "name": "Benralizumab", "description": "Benralizumab administered subcutaneously every 8 weeks", "armGroupLabels": ["Benralizumab Arm B"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Basophils, Full Analysis Set", "description": "Change from baseline in hematologic lab parameter of Basophils.", "timeFrame": "From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented."}, {"measure": "Change From Baseline in Leukocytes, Full Analysis Set", "description": "Change from baseline in hematologic lab parameter of Leukocytes.", "timeFrame": "From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented."}, {"measure": "Change From Baseline in Lymphocytes, Full Analysis Set", "description": "Change from baseline in hematologic lab parameter of Lymphocytes.", "timeFrame": "From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented."}, {"measure": "Change From Baseline in Neutrophils, Full Analysis Set", "description": "Change from baseline in hematologic lab parameter of Neutrophils.", "timeFrame": "From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented."}, {"measure": "Change From Baseline in Monocytes, Full Analysis Set", "description": "Change from baseline in hematologic lab parameter of Monocytes.", "timeFrame": "From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented."}, {"measure": "Change From Baseline in Platelets, Full Analysis Set", "description": "Change from baseline in hematologic lab parameter of Platelets.", "timeFrame": "From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented."}, {"measure": "Change From Baseline in Hematocrit, Full Analysis Set", "description": "Change from baseline in hematologic lab parameter of Hematocrit.", "timeFrame": "From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented."}, {"measure": "Change From Baseline in Erythrocytes, Full Analysis Set", "description": "Change from baseline in hematologic lab parameter of Erythrocytes.", "timeFrame": "From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented."}, {"measure": "Change From Baseline in Hemoglobin, Full Analysis Set", "description": "Change from baseline in hematologic lab parameter of Hemoglobin.", "timeFrame": "From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented."}, {"measure": "Change From Baseline in Alanine Aminotransferase (ALT), Full Analysis Set", "description": "Change from baseline in chemistry test ALT.", "timeFrame": "From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented."}, {"measure": "Change From Baseline in Aspartate Aminotransferase (AST), Full Analysis Set", "description": "Change from baseline in chemistry test AST.", "timeFrame": "From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented."}, {"measure": "Change From Baseline in Bilirubin, Full Analysis Set", "description": "Change from baseline in chemistry test Bilirubin.", "timeFrame": "From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented."}], "secondaryOutcomes": [{"measure": "Number of Participants With Asthma Exacerbations During Study Period", "description": "Asthma exacerbation is defined by a worsening of asthma requiring the use of systemic corticosteroids for at least 3 days, and/or an in patient hospitalization, and/or an emergency department or urgent care visit", "timeFrame": "From week 0 to week 184 in study treatment period and through the follow up period (12 weeks from day of last dose). Number and percentage of participants with asthma exacerbation during this period is presented."}, {"measure": "Number of Participants Who Had Health Care Encounter (ie, Hospitalization, Emergency Department Visits, Urgent Care Visits, and All Other Outpatient Visits Due to Asthma) During Study Period", "description": "Hospitalizations, Emergency department (ED) visits, urgent care visits and all other outpatient visits due to asthma", "timeFrame": "From week 0 to week 184 in study treatment period and through the follow up period (12 weeks from day of last dose). Number and percentage of participants with health care encounters during this period is presented."}, {"measure": "Change of Blood Eosinophils Count", "description": "Change from Baseline to End of Treatment in blood eosinophils count.", "timeFrame": "From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented."}, {"measure": "Number of Participants With Anti-drug Antibodies (ADA) Responses During the Study", "description": "Assessments for the presence of ADA and neutralizing antibody (nAb) throughout study", "timeFrame": "From week 0 to week 184 in study treatment period and plus 12 weeks follow up period"}, {"measure": "Duration of Exposure", "description": "Duration of exposure", "timeFrame": "From week 0 to week 184 in study treatment period"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Informed consent for study participation must be obtained prior to any study related procedures being performed and according to international guidelines and/or applicable European Union guidelines.\n* Female and male patients who have completed at least 16 and not more than 40 weeks in Study D3250C00021.\n* Women of childbearing potential (WOCBP) must agree to use an effective form of birth control throughout the study duration and for 16 weeks after the last dose of Investigational Product (IP)\n* For WOCBP only: Have a negative urine pregnancy test prior to administration of IP at Visit 1.\n* All male patients who are sexually active must agree to use a double barrier method of contraception (condom with spermicide) from the first dose of IP until 16 weeks after their last dose.\n\nExclusion Criteria:\n\n* Any disorder including but not limited to cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, hematological, psychiatric or major physical impairment that is not stable in the opinion of the Investigator and could:\n\n  * Affect the safety of the patient throughout the study\n  * Influence the findings of the study or their interpretations\n  * Impede the patient's ability to complete the entire duration of study\n* A helminth parasitic infection diagnosed during a predecessor study that has either required hospitalization, has not been treated, has been incompletely treated or has failed to respond to standard of care therapy\n* Any clinically significant change in physical examination, vital signs, ECG, hematology, clinical chemistry, or urinalysis during the predecessor study which in the opinion of the investigator may put the patient at risk because of his/her participation in the study, or may influence the results of the study, or interfere with the patient's ability to complete the entire duration of the study\n* Current malignancy or malignancy that developed during the predecessor study (subjects that had basal cell carcinoma, localized squamous cell carcinoma of the skin which was resected for cure, or in situ carcinoma of the cervix that has been treated/cured will not be excluded).\n* Receipt of live attenuated vaccines within 30 days prior to initiation of treatment in this study, during the treatment period, and for 16 weeks (5 half-lives) after the last dose of the IP\n* Receipt of immunoglobulin or blood products within 30 days prior to Visit 1\n* Planned major surgical procedures during the conduct of the study\n* Previous participation in the present study\n* Concurrent enrolment in another drug-related interventional clinical trial\n* AstraZeneca staff involved in the planning and/or conduct of the study\n* Employees of the study center or any other individuals involved with the conduct of the study or immediate family members of such individuals\n* Patients with important protocol deviations in the predecessor study at the discretion of the Sponsor\n* Patients with ongoing serious adverse events (SAEs) from the prior study should not be enrolled into the this extension study until the SAE has resolved", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "130 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"locations": [{"facility": "Research Site", "city": "Scottsboro", "state": "Alabama", "zip": "35768", "country": "United States", "geoPoint": {"lat": 34.67231, "lon": -86.03415}}, {"facility": "Research Site", "city": "Glendale", "state": "Arizona", "zip": "85306", "country": "United States", "geoPoint": {"lat": 33.53865, "lon": -112.18599}}, {"facility": "Research Site", "city": "Phoenix", "state": "Arizona", "zip": "85012", "country": "United States", "geoPoint": {"lat": 33.44838, "lon": -112.07404}}, {"facility": "Research Site", "city": "Bakersfield", "state": "California", "zip": "93301", "country": "United States", "geoPoint": {"lat": 35.37329, "lon": -119.01871}}, {"facility": "Research Site", "city": "Newport Beach", "state": "California", "zip": "92663", "country": "United States", "geoPoint": {"lat": 33.61891, "lon": -117.92895}}, {"facility": "Research Site", "city": "Redondo Beach", "state": "California", "zip": "90277", "country": "United States", "geoPoint": {"lat": 33.84918, "lon": -118.38841}}, {"facility": "Research Site", "city": "Roseville", "state": "California", "zip": "95661", "country": "United States", "geoPoint": {"lat": 38.75212, "lon": -121.28801}}, {"facility": "Research Site", "city": "Sacramento", "state": "California", "zip": "95825", "country": "United States", "geoPoint": {"lat": 38.58157, "lon": -121.4944}}, {"facility": "Research Site", "city": "San Jose", "state": "California", "zip": "95117", "country": "United States", "geoPoint": {"lat": 37.33939, "lon": -121.89496}}, {"facility": "Research Site", "city": "Stockton", "state": "California", "zip": "95204", "country": "United States", "geoPoint": {"lat": 37.9577, "lon": -121.29078}}, {"facility": "Research Site", "city": "Westminster", "state": "California", "zip": "92683", "country": "United States", "geoPoint": {"lat": 33.75918, "lon": -118.00673}}, {"facility": "Research Site", "city": "Woodland", "state": "California", "zip": "95695", "country": "United States", "geoPoint": {"lat": 38.67852, "lon": -121.7733}}, {"facility": "Research Site", "city": "Colorado Springs", "state": "Colorado", "zip": "80907", "country": "United States", "geoPoint": {"lat": 38.83388, "lon": -104.82136}}, {"facility": "Research Site", "city": "Denver", "state": "Colorado", "zip": "80206", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "Research Site", "city": "Wheat Ridge", "state": "Colorado", "zip": "80033", "country": "United States", "geoPoint": {"lat": 39.7661, "lon": -105.07721}}, {"facility": "Research Site", "city": "New Haven", "state": "Connecticut", "zip": "06520", "country": "United States", "geoPoint": {"lat": 41.30815, "lon": -72.92816}}, {"facility": "Research Site", "city": "Clearwater", "state": "Florida", "zip": "33765", "country": "United States", "geoPoint": {"lat": 27.96585, "lon": -82.8001}}, {"facility": "Research Site", "city": "Doral", "state": "Florida", "zip": "33172", "country": "United States", "geoPoint": {"lat": 25.81954, "lon": -80.35533}}, {"facility": "Research Site", "city": "Hialeah", "state": "Florida", "zip": "33012", "country": "United States", "geoPoint": {"lat": 25.8576, "lon": -80.27811}}, {"facility": "Research Site", "city": "Miami", "state": "Florida", "zip": "33134", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Research Site", "city": "Miami", "state": "Florida", "zip": "33144", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Research Site", "city": "Miami", "state": "Florida", "zip": "33176", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Research Site", "city": "Orlando", "state": "Florida", "zip": "32819", "country": "United States", "geoPoint": {"lat": 28.53834, "lon": -81.37924}}, {"facility": "Research Site", "city": "Orlando", "state": "Florida", "zip": "32825", "country": "United States", "geoPoint": {"lat": 28.53834, "lon": -81.37924}}, {"facility": "Research Site", "city": "Winter Park", "state": "Florida", "zip": "32789", "country": "United States", "geoPoint": {"lat": 28.6, "lon": -81.33924}}, {"facility": "Research Site", "city": "Iowa City", "state": "Iowa", "zip": "52242", "country": "United States", "geoPoint": {"lat": 41.66113, "lon": -91.53017}}, {"facility": "Research Site", "city": "Bangor", "state": "Maine", "zip": "04401", "country": "United States", "geoPoint": {"lat": 44.80118, "lon": -68.77781}}, {"facility": "Research Site", "city": "Quincy", "state": "Massachusetts", "zip": "02169", "country": "United States", "geoPoint": {"lat": 42.25288, "lon": -71.00227}}, {"facility": "Research Site", "city": "Farmington Hills", "state": "Michigan", "zip": "48334", "country": "United States", "geoPoint": {"lat": 42.48531, "lon": -83.37716}}, {"facility": "Research Site", "city": "Flint", "state": "Michigan", "zip": "48504", "country": "United States", "geoPoint": {"lat": 43.01253, "lon": -83.68746}}, {"facility": "Research Site", "city": "Traverse City", "state": "Michigan", "zip": "49686", "country": "United States", "geoPoint": {"lat": 44.76306, "lon": -85.62063}}, {"facility": "Research Site", "city": "Bronx", "state": "New York", "zip": "10461", "country": "United States", "geoPoint": {"lat": 40.84985, "lon": -73.86641}}, {"facility": "Research Site", "city": "New York", "state": "New York", "zip": "10016", "country": "United States", "geoPoint": {"lat": 40.71427, "lon": -74.00597}}, {"facility": "Research Site", "city": "Durham", "state": "North Carolina", "zip": "27705", "country": "United States", "geoPoint": {"lat": 35.99403, "lon": -78.89862}}, {"facility": "Research Site", "city": "Winston-Salem", "state": "North Carolina", "zip": "27103", "country": "United States", "geoPoint": {"lat": 36.09986, "lon": -80.24422}}, {"facility": "Research Site", "city": "Cincinnati", "state": "Ohio", "zip": "45231", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "Research Site", "city": "Middleburg Heights", "state": "Ohio", "zip": "44130", "country": "United States", "geoPoint": {"lat": 41.36144, "lon": -81.81291}}, {"facility": "Research Site", "city": "Oklahoma City", "state": "Oklahoma", "zip": "73103", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "Research Site", "city": "Oklahoma City", "state": "Oklahoma", "zip": "73120", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "Research Site", "city": "Jefferson Hills", "state": "Pennsylvania", "zip": "15025", "country": "United States", "geoPoint": {"lat": 40.29118, "lon": -79.93199}}, {"facility": "Research Site", "city": "Philadelphia", "state": "Pennsylvania", "zip": "19140", "country": "United States", "geoPoint": {"lat": 39.95233, "lon": -75.16379}}, {"facility": "Research Site", "city": "Hodges", "state": "South Carolina", "zip": "29653", "country": "United States", "geoPoint": {"lat": 34.28762, "lon": -82.24429}}, {"facility": "Research Site", "city": "Rapid City", "state": "South Dakota", "zip": "57702", "country": "United States", "geoPoint": {"lat": 44.08054, "lon": -103.23101}}, {"facility": "Research Site", "city": "Dallas", "state": "Texas", "zip": "75225", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "Research Site", "city": "Dallas", "state": "Texas", "zip": "75235", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "Research Site", "city": "Houston", "state": "Texas", "zip": "77058", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Research Site", "city": "Houston", "state": "Texas", "zip": "77081", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Research Site", "city": "Houston", "state": "Texas", "zip": "77083", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Research Site", "city": "McKinney", "state": "Texas", "zip": "75069", "country": "United States", "geoPoint": {"lat": 33.19762, "lon": -96.61527}}, {"facility": "Research Site", "city": "Abingdon", "state": "Virginia", "zip": "24210", "country": "United States", "geoPoint": {"lat": 36.70983, "lon": -81.97735}}, {"facility": "Research Site", "city": "Falls Church", "state": "Virginia", "zip": "22044", "country": "United States", "geoPoint": {"lat": 38.88233, "lon": -77.17109}}, {"facility": "Research Site", "city": "Madison", "state": "Wisconsin", "zip": "53792", "country": "United States", "geoPoint": {"lat": 43.07305, "lon": -89.40123}}, {"facility": "Research Site", "city": "Buenos Aires", "zip": "C1414AIF", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Research Site", "city": "Ciudad de Buenos Aire", "zip": "C1121 ABE", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Research Site", "city": "La Plata", "zip": "B1902COS", "country": "Argentina", "geoPoint": {"lat": -34.92145, "lon": -57.95453}}, {"facility": "Research Site", "city": "Mendoza", "zip": "5500", "country": "Argentina", "geoPoint": {"lat": -32.89084, "lon": -68.82717}}, {"facility": "Research Site", "city": "Mendoza", "zip": "M5500GIP", "country": "Argentina", "geoPoint": {"lat": -32.89084, "lon": -68.82717}}, {"facility": "Research Site", "city": "Frankston", "zip": "3199", "country": "Australia", "geoPoint": {"lat": -38.14458, "lon": 145.12291}}, {"facility": "Research Site", "city": "Nedlands", "zip": "6009", "country": "Australia", "geoPoint": {"lat": -31.98184, "lon": 115.8073}}, {"facility": "Research Site", "city": "Parkville", "zip": "3050", "country": "Australia", "geoPoint": {"lat": -37.78333, "lon": 144.95}}, {"facility": "Research Site", "city": "Randwick", "zip": "2031", "country": "Australia", "geoPoint": {"lat": -33.91439, "lon": 151.24895}}, {"facility": "Research Site", "city": "Woolloongabba", "zip": "4102", "country": "Australia", "geoPoint": {"lat": -27.48855, "lon": 153.03655}}, {"facility": "Research Site", "city": "Pazardzhik", "zip": "4400", "country": "Bulgaria", "geoPoint": {"lat": 42.2, "lon": 24.33333}}, {"facility": "Research Site", "city": "Pernik", "zip": "2300", "country": "Bulgaria", "geoPoint": {"lat": 42.6, "lon": 23.03333}}, {"facility": "Research Site", "city": "Petrich", "zip": "2850", "country": "Bulgaria", "geoPoint": {"lat": 41.39847, "lon": 23.20705}}, {"facility": "Research Site", "city": "Ruse", "zip": "7002", "country": "Bulgaria", "geoPoint": {"lat": 43.85639, "lon": 25.97083}}, {"facility": "Research Site", "city": "Sliven", "zip": "8800", "country": "Bulgaria", "geoPoint": {"lat": 42.68583, "lon": 26.32917}}, {"facility": "Research Site", "city": "Vratsa", "zip": "3000", "country": "Bulgaria", "geoPoint": {"lat": 43.21, "lon": 23.5625}}, {"facility": "Research Site", "city": "Calgary", "state": "Alberta", "zip": "T2N 4Z6", "country": "Canada", "geoPoint": {"lat": 51.05011, "lon": -114.08529}}, {"facility": "Research Site", "city": "Sherwood Park", "state": "Alberta", "zip": "T8L 0N2", "country": "Canada", "geoPoint": {"lat": 53.51684, "lon": -113.3187}}, {"facility": "Research Site", "city": "Vancouver", "state": "British Columbia", "zip": "V5Z 1M9", "country": "Canada", "geoPoint": {"lat": 49.24966, "lon": -123.11934}}, {"facility": "Research Site", "city": "Hamilton", "state": "Ontario", "zip": "L8N 4A6", "country": "Canada", "geoPoint": {"lat": 43.25011, "lon": -79.84963}}, {"facility": "Research Site", "city": "Ottawa", "state": "Ontario", "zip": "K1G 6C6", "country": "Canada", "geoPoint": {"lat": 45.41117, "lon": -75.69812}}, {"facility": "Research Site", "city": "Montreal", "state": "Quebec", "zip": "H2W 1T8", "country": "Canada", "geoPoint": {"lat": 45.50884, "lon": -73.58781}}, {"facility": "Research Site", "city": "Montreal", "state": "Quebec", "zip": "H4A 3J1", "country": "Canada", "geoPoint": {"lat": 45.50884, "lon": -73.58781}}, {"facility": "Research Site", "city": "Quebec", "zip": "G1G 3Y8", "country": "Canada", "geoPoint": {"lat": 46.81228, "lon": -71.21454}}, {"facility": "Research Site", "city": "Quebec", "zip": "G1V 4G5", "country": "Canada", "geoPoint": {"lat": 46.81228, "lon": -71.21454}}, {"facility": "Research Site", "city": "Quillota", "zip": "2260000", "country": "Chile", "geoPoint": {"lat": -32.88341, "lon": -71.24882}}, {"facility": "Research Site", "city": "Talcahuano", "zip": "4270918", "country": "Chile", "geoPoint": {"lat": -36.72494, "lon": -73.11684}}, {"facility": "Research Site", "city": "Valparaiso", "zip": "2341131", "country": "Chile", "geoPoint": {"lat": -33.03932, "lon": -71.62725}}, {"facility": "Research Site", "city": "Karlovy Vary", "zip": "360 17", "country": "Czechia", "geoPoint": {"lat": 50.23271, "lon": 12.87117}}, {"facility": "Research Site", "city": "Plzen", "zip": "304 60", "country": "Czechia", "geoPoint": {"lat": 49.74747, "lon": 13.37759}}, {"facility": "Research Site", "city": "Praha", "zip": "130 00", "country": "Czechia", "geoPoint": {"lat": 50.08804, "lon": 14.42076}}, {"facility": "Research Site", "city": "Rokycany", "zip": "337 22", "country": "Czechia", "geoPoint": {"lat": 49.7427, "lon": 13.59459}}, {"facility": "Research Site", "city": "Brest Cedex 2", "zip": "29609", "country": "France", "geoPoint": {"lat": 48.3903, "lon": -4.48628}}, {"facility": "Research Site", "city": "Dijon Cedex", "zip": "21079", "country": "France", "geoPoint": {"lat": 47.31667, "lon": 5.01667}}, {"facility": "Research Site", "city": "Le Kremlin Bic\u00eatre", "zip": "94275", "country": "France", "geoPoint": {"lat": 48.81471, "lon": 2.36073}}, {"facility": "Research Site", "city": "Le Mans Cedex", "zip": "72037", "country": "France", "geoPoint": {"lat": 48.0, "lon": 0.2}}, {"facility": "Research Site", "city": "Lyon Cedex 04", "zip": "69317", "country": "France", "geoPoint": {"lat": 45.74848, "lon": 4.84669}}, {"facility": "Research Site", "city": "Marseille Cedex 20", "zip": "13915", "country": "France", "geoPoint": {"lat": 43.29551, "lon": 5.38958}}, {"facility": "Research Site", "city": "Montpellier", "zip": "34295", "country": "France", "geoPoint": {"lat": 43.61092, "lon": 3.87723}}, {"facility": "Research Site", "city": "Paris", "zip": "75018", "country": "France", "geoPoint": {"lat": 48.85341, "lon": 2.3488}}, {"facility": "Research Site", "city": "Pringy Cedex", "zip": "74374", "country": "France", "geoPoint": {"lat": 45.94622, "lon": 6.12608}}, {"facility": "Research Site", "city": "Saint Pierre", "zip": "97448", "country": "France"}, {"facility": "Research Site", "city": "Strasbourg Cedex", "zip": "67091", "country": "France", "geoPoint": {"lat": 48.58392, "lon": 7.74553}}, {"facility": "Research Site", "city": "Toulouse Cedex 9", "zip": "31059", "country": "France", "geoPoint": {"lat": 43.60426, "lon": 1.44367}}, {"facility": "Research Site", "city": "Aschaffenburg", "zip": "63739", "country": "Germany", "geoPoint": {"lat": 49.97704, "lon": 9.15214}}, {"facility": "Research Site", "city": "Bamberg", "zip": "96049", "country": "Germany", "geoPoint": {"lat": 49.89873, "lon": 10.90067}}, {"facility": "Research Site", "city": "Berlin", "zip": "10367", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Research Site", "city": "Frankfurt/Main", "zip": "60389", "country": "Germany", "geoPoint": {"lat": 50.11552, "lon": 8.68417}}, {"facility": "Research Site", "city": "Frankfurt", "zip": "60596", "country": "Germany", "geoPoint": {"lat": 50.11552, "lon": 8.68417}}, {"facility": "Research Site", "city": "Geesthacht", "zip": "21502", "country": "Germany", "geoPoint": {"lat": 53.43575, "lon": 10.3779}}, {"facility": "Research Site", "city": "Grosshansdorf", "zip": "20927", "country": "Germany", "geoPoint": {"lat": 53.66667, "lon": 10.28333}}, {"facility": "Research Site", "city": "Hamburg", "zip": "22299", "country": "Germany", "geoPoint": {"lat": 53.57532, "lon": 10.01534}}, {"facility": "Research Site", "city": "Hannover", "zip": "D-30173", "country": "Germany", "geoPoint": {"lat": 52.37052, "lon": 9.73322}}, {"facility": "Research Site", "city": "Leipzig", "zip": "04103", "country": "Germany", "geoPoint": {"lat": 51.33962, "lon": 12.37129}}, {"facility": "Research Site", "city": "Leipzig", "zip": "04207", "country": "Germany", "geoPoint": {"lat": 51.33962, "lon": 12.37129}}, {"facility": "Research Site", "city": "Mainz", "zip": "55131", "country": "Germany", "geoPoint": {"lat": 49.98419, "lon": 8.2791}}, {"facility": "Research Site", "city": "Marburg", "zip": "30625", "country": "Germany", "geoPoint": {"lat": 50.80904, "lon": 8.77069}}, {"facility": "Research Site", "city": "R\u00fcdersdorf", "zip": "15562", "country": "Germany", "geoPoint": {"lat": 51.1, "lon": 11.45}}, {"facility": "Research Site", "city": "Aleksandr\u00f3w \u0141\u00f3dzki", "zip": "95-070", "country": "Poland", "geoPoint": {"lat": 51.81965, "lon": 19.30384}}, {"facility": "Research Site", "city": "Bia\u0142ystok", "zip": "15-430", "country": "Poland", "geoPoint": {"lat": 53.13333, "lon": 23.16433}}, {"facility": "Research Site", "city": "Bydgoszcz", "zip": "85-168", "country": "Poland", "geoPoint": {"lat": 53.1235, "lon": 18.00762}}, {"facility": "Research Site", "city": "Dobre Miasto", "zip": "11-040", "country": "Poland", "geoPoint": {"lat": 53.98668, "lon": 20.39749}}, {"facility": "Research Site", "city": "Gda\u0144sk", "zip": "80-214", "country": "Poland", "geoPoint": {"lat": 54.35205, "lon": 18.64637}}, {"facility": "Research Site", "city": "Gorz\u00f3w Wlkp", "zip": "66-400", "country": "Poland"}, {"facility": "Research Site", "city": "Grodzisk Mazowiecki", "zip": "05-825", "country": "Poland", "geoPoint": {"lat": 52.10387, "lon": 20.6337}}, {"facility": "Research Site", "city": "Ko\u015bcian", "zip": "64-000", "country": "Poland", "geoPoint": {"lat": 52.08829, "lon": 16.64866}}, {"facility": "Research Site", "city": "Krak\u00f3w", "zip": "31-011", "country": "Poland", "geoPoint": {"lat": 50.06143, "lon": 19.93658}}, {"facility": "Research Site", "city": "Krak\u00f3w", "zip": "31-033", "country": "Poland", "geoPoint": {"lat": 50.06143, "lon": 19.93658}}, {"facility": "Research Site", "city": "Lubin", "zip": "59-300", "country": "Poland", "geoPoint": {"lat": 51.40089, "lon": 16.20149}}, {"facility": "Research Site", "city": "Lublin", "zip": "20-552", "country": "Poland", "geoPoint": {"lat": 51.25, "lon": 22.56667}}, {"facility": "Research Site", "city": "Ostr\u00f3w Wielkopolski", "zip": "63-400", "country": "Poland", "geoPoint": {"lat": 51.65501, "lon": 17.80686}}, {"facility": "Research Site", "city": "Pozna\u0144", "zip": "60-685", "country": "Poland", "geoPoint": {"lat": 52.40692, "lon": 16.92993}}, {"facility": "Research Site", "city": "Pozna\u0144", "zip": "60-693", "country": "Poland", "geoPoint": {"lat": 52.40692, "lon": 16.92993}}, {"facility": "Research Site", "city": "Pozna\u0144", "zip": "60-823", "country": "Poland", "geoPoint": {"lat": 52.40692, "lon": 16.92993}}, {"facility": "Research Site", "city": "Proszowice", "zip": "32-100", "country": "Poland", "geoPoint": {"lat": 50.19275, "lon": 20.28909}}, {"facility": "Research Site", "city": "Ruda Slaska", "zip": "41-709", "country": "Poland", "geoPoint": {"lat": 50.2584, "lon": 18.85632}}, {"facility": "Research Site", "city": "Rzesz\u00f3w", "zip": "35-205", "country": "Poland", "geoPoint": {"lat": 50.04132, "lon": 21.99901}}, {"facility": "Research Site", "city": "Skierniewice", "zip": "96-100", "country": "Poland", "geoPoint": {"lat": 51.95485, "lon": 20.15837}}, {"facility": "Research Site", "city": "Sosnowiec", "zip": "41-200", "country": "Poland", "geoPoint": {"lat": 50.28682, "lon": 19.10385}}, {"facility": "Research Site", "city": "Tarn\u00f3w", "zip": "33-100", "country": "Poland", "geoPoint": {"lat": 50.01381, "lon": 20.98698}}, {"facility": "Research Site", "city": "Trzebnica", "zip": "55-100", "country": "Poland", "geoPoint": {"lat": 51.31076, "lon": 17.06331}}, {"facility": "Research Site", "city": "Warszawa", "zip": "01-138", "country": "Poland", "geoPoint": {"lat": 52.22977, "lon": 21.01178}}, {"facility": "Research Site", "city": "Warszawa", "zip": "01-868", "country": "Poland", "geoPoint": {"lat": 52.22977, "lon": 21.01178}}, {"facility": "Research Site", "city": "Wielu\u0144", "zip": "98-300", "country": "Poland", "geoPoint": {"lat": 51.22097, "lon": 18.56964}}, {"facility": "Research Site", "city": "Wo\u0142omin", "zip": "05-200", "country": "Poland", "geoPoint": {"lat": 52.34006, "lon": 21.24207}}, {"facility": "Research Site", "city": "Wroc\u0142aw", "zip": "50-220", "country": "Poland", "geoPoint": {"lat": 51.1, "lon": 17.03333}}, {"facility": "Research Site", "city": "Wroc\u0142aw", "zip": "51-162", "country": "Poland", "geoPoint": {"lat": 51.1, "lon": 17.03333}}, {"facility": "Research Site", "city": "Wroc\u0142aw", "zip": "53-301", "country": "Poland", "geoPoint": {"lat": 51.1, "lon": 17.03333}}, {"facility": "Research Site", "city": "\u0141\u00f3d\u017a", "zip": "90-141", "country": "Poland", "geoPoint": {"lat": 51.75, "lon": 19.46667}}, {"facility": "Research Site", "city": "\u0141\u00f3d\u017a", "zip": "91-103", "country": "Poland", "geoPoint": {"lat": 51.75, "lon": 19.46667}}, {"facility": "Research Site", "city": "\u017bnin", "zip": "88-400", "country": "Poland", "geoPoint": {"lat": 52.84958, "lon": 17.71992}}, {"facility": "Research Site", "city": "Ekaterinburg", "zip": "620039", "country": "Russian Federation", "geoPoint": {"lat": 56.8519, "lon": 60.6122}}, {"facility": "Research Site", "city": "Nizhny Novgorod", "zip": "603126", "country": "Russian Federation", "geoPoint": {"lat": 56.32867, "lon": 44.00205}}, {"facility": "Research Site", "city": "Saratov", "zip": "410053", "country": "Russian Federation", "geoPoint": {"lat": 51.54056, "lon": 46.00861}}, {"facility": "Research Site", "city": "Smolensk", "zip": "214019", "country": "Russian Federation", "geoPoint": {"lat": 54.7818, "lon": 32.0401}}, {"facility": "Research Site", "city": "St. Petersburg", "zip": "196247", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Research Site", "city": "Vladikavkaz", "zip": "362007", "country": "Russian Federation", "geoPoint": {"lat": 43.03667, "lon": 44.66778}}, {"facility": "Research Site", "city": "Volgograd", "zip": "400001", "country": "Russian Federation", "geoPoint": {"lat": 48.71939, "lon": 44.50183}}, {"facility": "Research Site", "city": "Volgograd", "zip": "400131", "country": "Russian Federation", "geoPoint": {"lat": 48.71939, "lon": 44.50183}}, {"facility": "Research Site", "city": "Yekaterinburg", "zip": "620149", "country": "Russian Federation", "geoPoint": {"lat": 56.8519, "lon": 60.6122}}, {"facility": "Research Site", "city": "M\u00e1laga", "zip": "29010", "country": "Spain", "geoPoint": {"lat": 36.72016, "lon": -4.42034}}, {"facility": "Research Site", "city": "Palma de Mallorca", "zip": "07010", "country": "Spain", "geoPoint": {"lat": 39.56939, "lon": 2.65024}}, {"facility": "Research Site", "city": "Sagunto(Valencia)", "zip": "46520", "country": "Spain"}, {"facility": "Research Site", "city": "Salamanca", "zip": "37007", "country": "Spain", "geoPoint": {"lat": 40.96882, "lon": -5.66388}}, {"facility": "Research Site", "city": "Valencia", "zip": "46015", "country": "Spain", "geoPoint": {"lat": 39.46975, "lon": -0.37739}}, {"facility": "Research Site", "city": "Valencia", "zip": "46017", "country": "Spain", "geoPoint": {"lat": 39.46975, "lon": -0.37739}}, {"facility": "Research Site", "city": "Adana", "zip": "01330", "country": "Turkey", "geoPoint": {"lat": 37.00167, "lon": 35.32889}}, {"facility": "Research Site", "city": "Ankara", "zip": "06230", "country": "Turkey", "geoPoint": {"lat": 39.91987, "lon": 32.85427}}, {"facility": "Research Site", "city": "Bursa", "zip": "16059", "country": "Turkey", "geoPoint": {"lat": 40.19559, "lon": 29.06013}}, {"facility": "Research Site", "city": "Istanbul", "zip": "34098", "country": "Turkey", "geoPoint": {"lat": 41.01384, "lon": 28.94966}}, {"facility": "Research Site", "city": "Dnipro", "zip": "49006", "country": "Ukraine", "geoPoint": {"lat": 48.4593, "lon": 35.03864}}, {"facility": "Research Site", "city": "Ivano-Frankivsk", "zip": "76018", "country": "Ukraine", "geoPoint": {"lat": 48.9215, "lon": 24.70972}}, {"facility": "Research Site", "city": "Kharkiv Region", "zip": "61022", "country": "Ukraine"}, {"facility": "Research Site", "city": "Kharkiv Region", "zip": "61035", "country": "Ukraine"}, {"facility": "Research Site", "city": "Kharkiv Region", "zip": "61039", "country": "Ukraine"}, {"facility": "Research Site", "city": "Kharkiv Region", "zip": "61058", "country": "Ukraine"}, {"facility": "Research Site", "city": "Kyiv", "zip": "03680", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "Research Site", "city": "Kyiv", "zip": "04201", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "Research Site", "city": "Lutsk", "zip": "4300", "country": "Ukraine", "geoPoint": {"lat": 50.75932, "lon": 25.34244}}, {"facility": "Research Site", "city": "Vinnytsia", "zip": "21029", "country": "Ukraine", "geoPoint": {"lat": 49.23278, "lon": 28.48097}}, {"facility": "Research Site", "city": "Birmingham", "zip": "B9 5SS", "country": "United Kingdom", "geoPoint": {"lat": 52.48142, "lon": -1.89983}}, {"facility": "Research Site", "city": "Cambridge", "zip": "CB2 0QQ", "country": "United Kingdom", "geoPoint": {"lat": 52.2, "lon": 0.11667}}, {"facility": "Research Site", "city": "Chertsey", "zip": "B9 5SS", "country": "United Kingdom", "geoPoint": {"lat": 51.38812, "lon": -0.50782}}, {"facility": "Research Site", "city": "Cottingham", "zip": "HU16 5JQ", "country": "United Kingdom", "geoPoint": {"lat": 52.50243, "lon": -0.7554}}, {"facility": "Research Site", "city": "Nottingham", "zip": "NG5 1PB", "country": "United Kingdom", "geoPoint": {"lat": 52.9536, "lon": -1.15047}}, {"facility": "Research Site", "city": "Stevenage", "zip": "SG1 4AB", "country": "United Kingdom", "geoPoint": {"lat": 51.90224, "lon": -0.20256}}]}, "referencesModule": {"seeAlsoLinks": [{"label": "CSP redacted.", "url": "https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D3250C00037&amp;attachmentIdentifier=c52ffe9a-53b4-40d3-935b-1b8ecf80bc07&amp;fileName=d3250c00037-revised-csp-2-redacted.pdf&amp;versionIdentifier="}, {"label": "SAP redacted.", "url": "https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D3250C00037&amp;attachmentIdentifier=d7b2554d-b014-4ffa-adec-c930fc06f4f5&amp;fileName=d3250c00037-sap-ed-2-redacted.pdf&amp;versionIdentifier="}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.", "infoTypes": ["STUDY_PROTOCOL", "SAP"], "timeFrame": "AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.", "accessCriteria": "When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.", "url": "https://astrazenecagroup-dt.pharmacm.com/DT/Home"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "170 participants from SIROCCO(NCT01928771)/CALIMA(NCT01914757) assigned to Benralizumab 30 mg every 4 weeks (q4w) with 1 participant not treated. 178 participants from SIROCCO/CALIMA received Benralizumab every 8 weeks (q8w). 51 participants from ZONDA(NCT02075255) received Benralizumab q4w. 48 participants from study ZONDA received Benralizumab q8w.", "recruitmentDetails": "447 patients enrolled in MELTEMI, 1 patient from Czech Republic was not treated, thus 446 patients received at least 1 dose of IP. Among these treated participants, 347 were from studies SIROCCO(NCT01928771)/CALIMA(NCT01914757) and 99 were from study ZONDA(NCT02075255).", "groups": [{"id": "FG000", "title": "Benra 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "FG001", "title": "Benra 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 8 weeks"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "220"}, {"groupId": "FG001", "numSubjects": "226"}]}, {"type": "Treated", "achievements": [{"groupId": "FG000", "numSubjects": "220"}, {"groupId": "FG001", "numSubjects": "226"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "189"}, {"groupId": "FG001", "numSubjects": "195"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "31"}, {"groupId": "FG001", "numSubjects": "31"}]}], "dropWithdraws": [{"type": "eg. no treatment efficacy on asthma", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "10"}, {"groupId": "FG001", "numSubjects": "13"}]}, {"type": "Site terminated by sponsor", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Pregnancy", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "6"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Development of study-specific withdrawal criteria", "reasons": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "4"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Full analysis set is defined to include subjects who received at least 1 dose of investigational product (IP).", "groups": [{"id": "BG000", "title": "Benra 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "BG001", "title": "Benra 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 8 weeks"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "220"}, {"groupId": "BG001", "value": "226"}, {"groupId": "BG002", "value": "446"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "53.5", "spread": "12.00"}, {"groupId": "BG001", "value": "53.0", "spread": "11.64"}, {"groupId": "BG002", "value": "53.2", "spread": "11.81"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "140"}, {"groupId": "BG001", "value": "144"}, {"groupId": "BG002", "value": "284"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "80"}, {"groupId": "BG001", "value": "82"}, {"groupId": "BG002", "value": "162"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "204"}, {"groupId": "BG001", "value": "206"}, {"groupId": "BG002", "value": "410"}]}]}, {"title": "Black or African", "categories": [{"measurements": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "13"}, {"groupId": "BG002", "value": "22"}]}]}, {"title": "American Asian", "categories": [{"measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "8"}]}]}, {"title": "Other", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "6"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Basophils, Full Analysis Set", "description": "Change from baseline in hematologic lab parameter of Basophils.", "populationDescription": "Full analysis set. For each lab test, number of patients is the number of patients with available change from baseline value.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "10^9 cells/L", "timeFrame": "From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.", "groups": [{"id": "OG000", "title": "Benra 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benra 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 8 weeks"}, {"id": "OG002", "title": "Total", "description": "sum per row"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "173"}, {"groupId": "OG001", "value": "178"}, {"groupId": "OG002", "value": "351"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.014", "spread": "0.0229"}, {"groupId": "OG001", "value": "0.012", "spread": "0.0243"}, {"groupId": "OG002", "value": "0.013", "spread": "0.0236"}]}]}]}, {"type": "PRIMARY", "title": "Change From Baseline in Leukocytes, Full Analysis Set", "description": "Change from baseline in hematologic lab parameter of Leukocytes.", "populationDescription": "Full analysis set. For each lab test, number of patients is the number of patients with available change from baseline value.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "10^9 cells/L", "timeFrame": "From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.", "groups": [{"id": "OG000", "title": "Benra 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benra 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 8 weeks"}, {"id": "OG002", "title": "Total", "description": "sum per row"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "178"}, {"groupId": "OG001", "value": "182"}, {"groupId": "OG002", "value": "360"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.254", "spread": "2.0446"}, {"groupId": "OG001", "value": "-0.498", "spread": "1.7217"}, {"groupId": "OG002", "value": "-0.377", "spread": "1.8896"}]}]}]}, {"type": "PRIMARY", "title": "Change From Baseline in Lymphocytes, Full Analysis Set", "description": "Change from baseline in hematologic lab parameter of Lymphocytes.", "populationDescription": "Full analysis set. For each lab test, number of patients is the number of patients with available change from baseline value.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "10^9 cells/L", "timeFrame": "From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.", "groups": [{"id": "OG000", "title": "Benra 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benra 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 8 weeks"}, {"id": "OG002", "title": "Total", "description": "sum per row"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "173"}, {"groupId": "OG001", "value": "178"}, {"groupId": "OG002", "value": "351"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.098", "spread": "0.5479"}, {"groupId": "OG001", "value": "-0.142", "spread": "0.6544"}, {"groupId": "OG002", "value": "-0.121", "spread": "0.6038"}]}]}]}, {"type": "PRIMARY", "title": "Change From Baseline in Neutrophils, Full Analysis Set", "description": "Change from baseline in hematologic lab parameter of Neutrophils.", "populationDescription": "Full analysis set. For each lab test, number of patients is the number of patients with available change from baseline value.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "10^9 cells/L", "timeFrame": "From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.", "groups": [{"id": "OG000", "title": "Benra 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benra 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 8 weeks"}, {"id": "OG002", "title": "Total", "description": "sum per row"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "173"}, {"groupId": "OG001", "value": "178"}, {"groupId": "OG002", "value": "351"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.237", "spread": "1.8765"}, {"groupId": "OG001", "value": "-0.392", "spread": "1.4802"}, {"groupId": "OG002", "value": "-0.315", "spread": "1.6866"}]}]}]}, {"type": "PRIMARY", "title": "Change From Baseline in Monocytes, Full Analysis Set", "description": "Change from baseline in hematologic lab parameter of Monocytes.", "populationDescription": "Full analysis set. For each lab test, number of patients is the number of patients with available change from baseline value.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "10^9 cells/L", "timeFrame": "From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.", "groups": [{"id": "OG000", "title": "Benra 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benra 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 8 weeks"}, {"id": "OG002", "title": "Total", "description": "sum per row"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "173"}, {"groupId": "OG001", "value": "179"}, {"groupId": "OG002", "value": "352"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.055", "spread": "0.1835"}, {"groupId": "OG001", "value": "0.056", "spread": "0.1766"}, {"groupId": "OG002", "value": "0.055", "spread": "0.1798"}]}]}]}, {"type": "PRIMARY", "title": "Change From Baseline in Platelets, Full Analysis Set", "description": "Change from baseline in hematologic lab parameter of Platelets.", "populationDescription": "Full analysis set. For each lab test, number of patients is the number of patients with available change from baseline value.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "10^9 cells/L", "timeFrame": "From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.", "groups": [{"id": "OG000", "title": "Benra 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benra 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 8 weeks"}, {"id": "OG002", "title": "Total", "description": "sum per row"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "177"}, {"groupId": "OG001", "value": "179"}, {"groupId": "OG002", "value": "356"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "9.1", "spread": "41.72"}, {"groupId": "OG001", "value": "11.9", "spread": "36.13"}, {"groupId": "OG002", "value": "10.5", "spread": "38.98"}]}]}]}, {"type": "PRIMARY", "title": "Change From Baseline in Hematocrit, Full Analysis Set", "description": "Change from baseline in hematologic lab parameter of Hematocrit.", "populationDescription": "Full analysis set. For each lab test, number of patients is the number of patients with available change from baseline value.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "[ratio]", "timeFrame": "From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.", "groups": [{"id": "OG000", "title": "Benra 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benra 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 8 weeks"}, {"id": "OG002", "title": "Total", "description": "sum per row"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "172"}, {"groupId": "OG001", "value": "177"}, {"groupId": "OG002", "value": "349"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.002", "spread": "0.0269"}, {"groupId": "OG001", "value": "-0.003", "spread": "0.0260"}, {"groupId": "OG002", "value": "-0.003", "spread": "0.0264"}]}]}]}, {"type": "PRIMARY", "title": "Change From Baseline in Erythrocytes, Full Analysis Set", "description": "Change from baseline in hematologic lab parameter of Erythrocytes.", "populationDescription": "Full analysis set. For each lab test, number of patients is the number of patients with available change from baseline value.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "10^12 cells/L", "timeFrame": "From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.", "groups": [{"id": "OG000", "title": "Benra 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benra 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 8 weeks"}, {"id": "OG002", "title": "Total", "description": "sum per row"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "178"}, {"groupId": "OG001", "value": "183"}, {"groupId": "OG002", "value": "361"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.008", "spread": "0.2922"}, {"groupId": "OG001", "value": "-0.054", "spread": "0.2614"}, {"groupId": "OG002", "value": "-0.031", "spread": "0.2776"}]}]}]}, {"type": "PRIMARY", "title": "Change From Baseline in Hemoglobin, Full Analysis Set", "description": "Change from baseline in hematologic lab parameter of Hemoglobin.", "populationDescription": "Full analysis set. For each lab test, number of patients is the number of patients with available change from baseline value.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "g/L", "timeFrame": "From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.", "groups": [{"id": "OG000", "title": "Benra 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benra 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 8 weeks"}, {"id": "OG002", "title": "Total", "description": "sum per row"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "178"}, {"groupId": "OG001", "value": "183"}, {"groupId": "OG002", "value": "361"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.6", "spread": "8.92"}, {"groupId": "OG001", "value": "1.2", "spread": "8.37"}, {"groupId": "OG002", "value": "1.9", "spread": "8.66"}]}]}]}, {"type": "PRIMARY", "title": "Change From Baseline in Alanine Aminotransferase (ALT), Full Analysis Set", "description": "Change from baseline in chemistry test ALT.", "populationDescription": "Full analysis set. For each lab test, number of patients is the number of patients with available change from baseline value.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ukat/L", "timeFrame": "From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.", "groups": [{"id": "OG000", "title": "Benra 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benra 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 8 weeks"}, {"id": "OG002", "title": "Total", "description": "sum per row"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "174"}, {"groupId": "OG001", "value": "175"}, {"groupId": "OG002", "value": "349"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.007", "spread": "0.2060"}, {"groupId": "OG001", "value": "0.004", "spread": "0.2118"}, {"groupId": "OG002", "value": "0.005", "spread": "0.2086"}]}]}]}, {"type": "PRIMARY", "title": "Change From Baseline in Aspartate Aminotransferase (AST), Full Analysis Set", "description": "Change from baseline in chemistry test AST.", "populationDescription": "Full analysis set. For each lab test, number of patients is the number of patients with available change from baseline value.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ukat/L", "timeFrame": "From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.", "groups": [{"id": "OG000", "title": "Benra 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benra 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 8 weeks"}, {"id": "OG002", "title": "Total", "description": "sum per row"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "174"}, {"groupId": "OG001", "value": "175"}, {"groupId": "OG002", "value": "349"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.021", "spread": "0.1258"}, {"groupId": "OG001", "value": "-0.018", "spread": "0.1280"}, {"groupId": "OG002", "value": "-0.020", "spread": "0.1267"}]}]}]}, {"type": "PRIMARY", "title": "Change From Baseline in Bilirubin, Full Analysis Set", "description": "Change from baseline in chemistry test Bilirubin.", "populationDescription": "Full analysis set. For each lab test, number of patients is the number of patients with available change from baseline value.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "umol/L", "timeFrame": "From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.", "groups": [{"id": "OG000", "title": "Benra 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benra 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 8 weeks"}, {"id": "OG002", "title": "Total", "description": "sum per row"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "172"}, {"groupId": "OG001", "value": "175"}, {"groupId": "OG002", "value": "347"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.451", "spread": "3.0980"}, {"groupId": "OG001", "value": "-0.297", "spread": "3.3972"}, {"groupId": "OG002", "value": "-0.374", "spread": "3.2486"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Asthma Exacerbations During Study Period", "description": "Asthma exacerbation is defined by a worsening of asthma requiring the use of systemic corticosteroids for at least 3 days, and/or an in patient hospitalization, and/or an emergency department or urgent care visit", "populationDescription": "Full analysis set.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "From week 0 to week 184 in study treatment period and through the follow up period (12 weeks from day of last dose). Number and percentage of participants with asthma exacerbation during this period is presented.", "groups": [{"id": "OG000", "title": "Benra 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benra 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 8 weeks"}, {"id": "OG002", "title": "Total", "description": "sum per row"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "220"}, {"groupId": "OG001", "value": "226"}, {"groupId": "OG002", "value": "446"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "96"}, {"groupId": "OG001", "value": "97"}, {"groupId": "OG002", "value": "193"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants Who Had Health Care Encounter (ie, Hospitalization, Emergency Department Visits, Urgent Care Visits, and All Other Outpatient Visits Due to Asthma) During Study Period", "description": "Hospitalizations, Emergency department (ED) visits, urgent care visits and all other outpatient visits due to asthma", "populationDescription": "Full analysis set.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "From week 0 to week 184 in study treatment period and through the follow up period (12 weeks from day of last dose). Number and percentage of participants with health care encounters during this period is presented.", "groups": [{"id": "OG000", "title": "Benra 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benra 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 8 weeks"}, {"id": "OG002", "title": "Total", "description": "sum per row"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "220"}, {"groupId": "OG001", "value": "226"}, {"groupId": "OG002", "value": "446"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "25"}, {"groupId": "OG001", "value": "28"}, {"groupId": "OG002", "value": "53"}]}]}]}, {"type": "SECONDARY", "title": "Change of Blood Eosinophils Count", "description": "Change from Baseline to End of Treatment in blood eosinophils count.", "populationDescription": "Full analysis set.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "cell/uL", "timeFrame": "From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.", "groups": [{"id": "OG000", "title": "Benra 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benra 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 8 weeks"}, {"id": "OG002", "title": "Total", "description": "sum per row"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "173"}, {"groupId": "OG001", "value": "178"}, {"groupId": "OG002", "value": "351"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "12.3", "spread": "50.24"}, {"groupId": "OG001", "value": "-12.9", "spread": "212.51"}, {"groupId": "OG002", "value": "-0.5", "spread": "155.68"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Anti-drug Antibodies (ADA) Responses During the Study", "description": "Assessments for the presence of ADA and neutralizing antibody (nAb) throughout study", "populationDescription": "Full analysis set.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "From week 0 to week 184 in study treatment period and plus 12 weeks follow up period", "groups": [{"id": "OG000", "title": "Benra 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benra 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 8 weeks"}, {"id": "OG002", "title": "Total", "description": "sum per row"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "220"}, {"groupId": "OG001", "value": "226"}, {"groupId": "OG002", "value": "446"}]}], "classes": [{"title": "Positive at any visit", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "218"}, {"groupId": "OG001", "value": "225"}, {"groupId": "OG002", "value": "443"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "28"}, {"groupId": "OG002", "value": "47"}]}]}, {"title": "Both baseline and post-baseline positive", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "206"}, {"groupId": "OG001", "value": "214"}, {"groupId": "OG002", "value": "420"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "17"}, {"groupId": "OG002", "value": "28"}]}]}, {"title": "Only post-baseline positive", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "211"}, {"groupId": "OG001", "value": "218"}, {"groupId": "OG002", "value": "429"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "10"}, {"groupId": "OG002", "value": "17"}]}]}, {"title": "ADA Persistently Positive", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "211"}, {"groupId": "OG001", "value": "218"}, {"groupId": "OG002", "value": "429"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "21"}, {"groupId": "OG002", "value": "33"}]}]}, {"title": "ADA Transiently Positive", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "211"}, {"groupId": "OG001", "value": "218"}, {"groupId": "OG002", "value": "429"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "6"}, {"groupId": "OG002", "value": "12"}]}]}, {"title": "Only baseline positive", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "213"}, {"groupId": "OG001", "value": "221"}, {"groupId": "OG002", "value": "434"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "2"}]}]}, {"title": "nAb positive", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "218"}, {"groupId": "OG001", "value": "225"}, {"groupId": "OG002", "value": "443"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "13"}, {"groupId": "OG001", "value": "24"}, {"groupId": "OG002", "value": "37"}]}]}, {"title": "nAb positive in ADA positive participants", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "28"}, {"groupId": "OG002", "value": "47"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "13"}, {"groupId": "OG001", "value": "24"}, {"groupId": "OG002", "value": "37"}]}]}]}, {"type": "SECONDARY", "title": "Duration of Exposure", "description": "Duration of exposure", "populationDescription": "Full analysis set.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "months", "timeFrame": "From week 0 to week 184 in study treatment period", "groups": [{"id": "OG000", "title": "Benra 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benra 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 8 weeks"}, {"id": "OG002", "title": "Total", "description": "sum per row"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "220"}, {"groupId": "OG001", "value": "226"}, {"groupId": "OG002", "value": "446"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "26.35", "spread": "10.112"}, {"groupId": "OG001", "value": "25.36", "spread": "9.939"}, {"groupId": "OG002", "value": "25.85", "spread": "10.026"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "3", "timeFrame": "All participants completed treatment period up to Week 184.", "eventGroups": [{"id": "EG000", "title": "Benra 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks", "deathsNumAffected": 1, "deathsNumAtRisk": 220, "seriousNumAffected": 44, "seriousNumAtRisk": 220, "otherNumAffected": 169, "otherNumAtRisk": 220}, {"id": "EG001", "title": "Benra 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 8 weeks", "deathsNumAffected": 0, "deathsNumAtRisk": 226, "seriousNumAffected": 47, "seriousNumAtRisk": 226, "otherNumAffected": 145, "otherNumAtRisk": 226}], "seriousEvents": [{"term": "Hypochromic anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 226}]}, {"term": "Lymphadenitis", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 226}]}, {"term": "Aortic valve stenosis", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 226}]}, {"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 226}]}, {"term": "Coronary artery occlusion", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 226}]}, {"term": "Left ventricular failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 226}]}, {"term": "Hyperthyroidism", "organSystem": "Endocrine disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 226}]}, {"term": "Cataract", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 226}]}, {"term": "Retinal tear", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 226}]}, {"term": "Abdominal pain upper", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 226}]}, {"term": "Anal stenosis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 226}]}, {"term": "Femoral hernia incarcerated", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 226}]}, {"term": "Gastrointestinal haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 226}]}, {"term": "Gastrooesophageal reflux disease", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 226}]}, {"term": "Haemorrhoids", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 226}]}, {"term": "Hiatus hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 226}]}, {"term": "Large intestine polyp", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 226}]}, {"term": "Asthenia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 226}]}, {"term": "Musculoskeletal complication associated with device", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 226}]}, {"term": "Non-cardiac chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 226}]}, {"term": "Bile duct stone", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 226}]}, {"term": "Cholecystitis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 226}]}, {"term": "Anaphylactic reaction", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 226}]}, {"term": "Hypersensitivity", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 226}]}, {"term": "Abscess limb", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 226}]}, {"term": "Appendicitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 226}]}, {"term": "Cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 226}]}, {"term": "Chronic sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 226}]}, {"term": "Erysipelas", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 226}]}, {"term": "Graft infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 226}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 3, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 226}]}, {"term": "Otitis media", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 226}]}, {"term": "Periorbital cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 226}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 226}]}, {"term": "Pulmonary tuberculosis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 226}]}, {"term": "Respiratory tract infection bacterial", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 226}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 226}]}, {"term": "Tonsillitis bacterial", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 226}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 226}]}, {"term": "Hip fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 226}]}, {"term": "Humerus fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 226}]}, {"term": "Limb injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 226}]}, {"term": "Lower limb fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 226}]}, {"term": "Procedural nausea", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 226}]}, {"term": "Road traffic accident", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 226}]}, {"term": "Stoma complication", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 226}]}, {"term": "Tendon rupture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 226}]}, {"term": "Blood lactic acid increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 226}]}, {"term": "Gout", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 226}]}, {"term": "Obesity", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 226}]}, {"term": "Bone deformity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 226}]}, {"term": "Intervertebral disc degeneration", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 226}]}, {"term": "Intervertebral disc protrusion", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 3, "numAffected": 1, "numAtRisk": 226}]}, {"term": "Joint range of motion decreased", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 226}]}, {"term": "Ligament laxity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 226}]}, {"term": "Osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 226}]}, {"term": "Spinal osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 226}]}, {"term": "Adenocarcinoma of colon", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 226}]}, {"term": "Basal cell carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 226}]}, {"term": "Gastrointestinal tract adenoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 226}]}, {"term": "Papillary thyroid cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 226}]}, {"term": "Prostate cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 226}]}, {"term": "Silicon granuloma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 226}]}, {"term": "Transitional cell carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 226}]}, {"term": "Carotid artery aneurysm", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 226}]}, {"term": "Cerebrospinal fluid leakage", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 226}]}, {"term": "Embolic stroke", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 226}]}, {"term": "Haemorrhagic stroke", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 226}]}, {"term": "Ischaemic stroke", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 226}]}, {"term": "Lumbar radiculopathy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 226}]}, {"term": "Migraine", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 226}]}, {"term": "Sciatica", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 226}]}, {"term": "Syncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 226}]}, {"term": "Transient global amnesia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 226}]}, {"term": "Transient ischaemic attack", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 226}]}, {"term": "Depression", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 226}]}, {"term": "Uterovaginal prolapse", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 226}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 15, "numAffected": 9, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 19, "numAffected": 13, "numAtRisk": 226}]}, {"term": "Bronchiectasis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 226}]}, {"term": "Chronic obstructive pulmonary disease", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 226}]}, {"term": "Nasal polyps", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 226}]}, {"term": "Nasal turbinate hypertrophy", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 226}]}, {"term": "Pulmonary embolism", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 226}]}, {"term": "Pulmonary mass", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 226}]}, {"term": "Respiratory failure", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 226}]}, {"term": "Angioedema", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 226}]}, {"term": "Eczema", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 226}]}, {"term": "Aortic aneurysm", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 226}]}, {"term": "Polyarteritis nodosa", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 226}]}], "otherEvents": [{"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 12, "numAffected": 8, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 6, "numAffected": 6, "numAtRisk": 226}]}, {"term": "Influenza like illness", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 9, "numAffected": 7, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 10, "numAffected": 8, "numAtRisk": 226}]}, {"term": "Acute sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 20, "numAffected": 13, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 10, "numAffected": 8, "numAtRisk": 226}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 33, "numAffected": 23, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 26, "numAffected": 22, "numAtRisk": 226}]}, {"term": "Bronchitis bacterial", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 17, "numAffected": 12, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 13, "numAffected": 9, "numAtRisk": 226}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 6, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 10, "numAffected": 10, "numAtRisk": 226}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 126, "numAffected": 67, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 112, "numAffected": 64, "numAtRisk": 226}]}, {"term": "Pharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 19, "numAffected": 10, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 226}]}, {"term": "Rhinitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 18, "numAffected": 11, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 226}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 26, "numAffected": 17, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 16, "numAffected": 10, "numAtRisk": 226}]}, {"term": "Sinusitis bacterial", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 4, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 10, "numAffected": 7, "numAtRisk": 226}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 20, "numAffected": 14, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 12, "numAffected": 8, "numAtRisk": 226}]}, {"term": "Upper respiratory tract infection bacterial", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 19, "numAffected": 10, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 10, "numAffected": 8, "numAtRisk": 226}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 9, "numAffected": 7, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 7, "numAffected": 7, "numAtRisk": 226}]}, {"term": "Viral upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 38, "numAffected": 29, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 21, "numAffected": 19, "numAtRisk": 226}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 7, "numAffected": 7, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 9, "numAffected": 8, "numAtRisk": 226}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 14, "numAffected": 11, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 10, "numAffected": 10, "numAtRisk": 226}]}, {"term": "Osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 14, "numAffected": 10, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 226}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 9, "numAffected": 7, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 226}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 56, "numAffected": 32, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 41, "numAffected": 21, "numAtRisk": 226}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 21, "numAffected": 16, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 40, "numAffected": 20, "numAtRisk": 226}]}, {"term": "Nasal polyps", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 10, "numAffected": 7, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 226}]}, {"term": "Rhinitis allergic", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 8, "numAffected": 4, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 12, "numAffected": 8, "numAtRisk": 226}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 23, "numAffected": 14, "numAtRisk": 220}, {"groupId": "EG001", "numEvents": 31, "numAffected": 24, "numAtRisk": 226}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "All participants in this study had to complete treatment in predecessor studies. Therefore selection bias may exist. Baseline is defined for this study's entry value, not the value prior to Benralizumab treatment. All participants have been treated with Benralizumab prior to this study's entry."}, "certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "\u2265 60 days prior to submission of material for publication/presentation, Institution and PI shall jointly provide AZ with material for review. No publication/presentation may include any of AZ's Confidential Information without AZ's written approval. AZ can request Inst. and PI to withhold material from submission for publication/presentation for an additional 90 days to allow AZ to establish and preserve its proprietary rights in the material being submitted for publication or presentation."}, "pointOfContact": {"title": "AstraZeneca Information Center", "organization": "AstraZeneca", "email": "information.center@astrazeneca.com", "phone": "+1 8002369933"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2019-10-14", "uploadDate": "2021-02-10T03:47", "filename": "Prot_000.pdf", "size": 2939153}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2020-07-16", "uploadDate": "2021-02-10T03:48", "filename": "SAP_001.pdf", "size": 650857}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Czech Republic", "Peru", "Philippines"]}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "C000571386", "term": "Benralizumab"}], "ancestors": [{"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}], "browseLeaves": [{"id": "M287399", "name": "Benralizumab", "asFound": "Aorta", "relevance": "HIGH"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}